Retatrutide Hits 28.7% Weight Loss, Triggers IP Battle Across 27 Programs
Eli Lilly’s retatrutide achieved 28.7% mean weight loss in April 2026, marking the first non-surgical therapy to match bariatric surgery outcomes; 27 triple-agonist programs are now in development across Novo Nordisk, Pfizer, Hanmi, Innovent, Hengrui, and Sanofi. The PatentVest report maps the IP battle shaping access and value capture in the post-28.7% “Last 20%” phase.
1. Retatrutide Achieves Surgery-Level Weight Loss
In April 2026, Eli Lilly reported that retatrutide delivered a mean 28.7% weight reduction in clinical trials, the first non-surgical therapy to reach outcomes on par with bariatric surgery, setting a new benchmark for obesity treatment.
2. Expanding Triple-Agonist Pipeline
A total of 27 competing triple-agonist programs are advancing, with Novo Nordisk building multiple assets, Pfizer entering via acquisition, Hanmi progressing a small-molecule candidate, and Innovent, Hengrui and other Chinese sponsors scaling development depth while Sanofi holds a dominant IP position.
3. IP Control and the “Last 20%” Race
With the mechanism validated, the focus shifts to intellectual property strategy: who can navigate around existing patents, who will be blocked from market entry and who will pay to participate, as the gap between trial results and real-world outcomes becomes the decisive battleground for value capture.